Antibodies for bioanalysis and drug monitoring of secukinumab and biosimilars

Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody secukinumab (Cosentyx) using our range of ready-made antibodies.

  • Highly specific to secukinumab or the secukinumab-IL17A complex
  • Fully human format for surrogate positive control or calibrator
  • Sequence-defined, well characterized reagents with secure supply
  • Stringent quality control for batch-to-batch consistency
  • Nonanimal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Secukinumab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Secukinumab

Inhibitory

Type 1

HCA370

AbD37052

Fab-FH1

5

PK bridging ELISA

Order HCA370

HCA371

AbD37054ia

Human IgG1

3

PK bridging ELISA

ADA control

Order HCA371

HCA372

AbD37091ia

Human IgG1

5

PK bridging ELISA

ADA control

Order HCA372

HCA373

AbD36536ia

Human IgG1

12

ADA control

Order HCA373

Secukinumab-IL17A Complex Specific

Type 3

 

HCA375

AbD36949

Fab-FH1

7

PK antigen capture ELISA

Order HCA375

* Affinity measured in the monovalent Fab format.
1 Monovalent Fab antibody (F) DYKDDDDK- and (H) His-6-tags


Anti-Secukinumab Inhibitory Antibodies (Type 1)

Type 1 anti-secukinumab antibodies inhibit the binding of the monoclonal antibody drug secukinumab to its target, human interleukin 17A (IL-17A). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. They are available in fully human IgG1 format, in three different affinities, for use as a surrogate positive control or reference standard for an anti-drug antibody (ADA) assay.


Anti-Secukinumab-IL17A Complex Specific Antibody (Type 3)

The Type 3 antibody specifically recognizes the drug-target complex, detecting secukinumab only when it is bound to IL17A. It is suitable as a detection antibody in a PK antigen capture assay, as an alternative assay format to the bridging ELISA.


ELISA Protocols to Get You Started

PK Bridging ELISA


Fig. 1. Secukinumab PK bridging ELISA using antibodies HCA370 and HCA372.

Fig. 1. Secukinumab PK bridging ELISA using antibodies HCA370 and HCA372.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.


PK Antigen Capture ELISA


Fig. 2. Secukinumab PK antigen capture ELISA using antibody HCA375.

Fig. 2. Secukinumab PK antigen capture ELISA using antibody HCA375.

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), anti-tag detection antibody labeled with HRP (gray).

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), anti-tag detection antibody labeled with HRP (gray).


ADA Bridging ELISA


Fig. 3. Secukinumab ADA bridging ELISA using antibody HCA371, HCA372, or HCA373.

Fig. 3. Secukinumab ADA bridging ELISA using antibody HCA371, HCA372, or HCA373.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).


Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.